CAPTRUST Financial Advisors
LMDXW

CAPTRUST Financial Advisors’s LumiraDx Limited Warrant LMDXW Stock Holding History

CAPTRUST Financial Advisors’s Portfolio LMDXW Stock Details LMDXW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-20,000
Closed -$172 – 2738
2023
Q4 		$172 Hold
20,000
– – ﹤0.01% 2652
2023
Q3 		$580 Hold
20,000
– – ﹤0.01% 2577
2023
Q2 		$302 Buy
+20,000
New +$1.1K ﹤0.01% 2521

Other funds holding LMDXW

CH
CVS Health Woonsocket, Rhode Island $212M AUM 19.39% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

CAPTRUST Financial Advisors's LMDXW Position: Q1 2024 in Review

CAPTRUST Financial Advisors sold out of LumiraDx Limited Warrant (LMDXW) in Q1 2024, closing a stake of 20,000 shares — an estimated $172 sold.

CAPTRUST Financial Advisors first reported a position in LMDXW in Q2 2023 and held it in 3 quarters. The position peaked at $580 in Q3 2023. 4 funds tracked by Wall St. Rank hold LMDXW as of Q1 2024.

  • CAPTRUST Financial Advisors reported no remaining LumiraDx Limited Warrant position as of Q1 2024 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 20,000 LumiraDx Limited Warrant shares in Q1 2024, an estimated $172.
  • CAPTRUST Financial Advisors first reported a position in LumiraDx Limited Warrant in Q2 2023 and held it in 3 quarters.
  • CAPTRUST Financial Advisors's LumiraDx Limited Warrant position peaked at $580 in Q3 2023.
  • 4 funds tracked by Wall St. Rank held LumiraDx Limited Warrant as of Q1 2024.

Based on CAPTRUST Financial Advisors's 13F filing for Q1 2024, filed 15 May 2024.